XORTX Therapeutics Inc (XRTX)
NASDAQ:XRTX
XRTX Stock Chart & Stats
$0.58
-$0.02(-1.68%)
At close: 4:00 PM EST
$0.58
-$0.02(-1.68%)
Day’s Range― - ―
52-Week Range$1.73 - $7.05
Previous CloseN/A
Volume19.17K
Average Volume (3M)3.79M
Market Cap
$3.55M
Enterprise Value$402.49K
Total Cash (Recent Filing)$250.45K
Total Debt (Recent Filing)$15.07K
Price to Earnings (P/E)―
Beta0.49
Next Earnings
Aug 13, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-10.94
Shares Outstanding1,546,988
10 Day Avg. Volume11,302,330
30 Day Avg. Volume3,791,937
Financial Highlights & Ratios
PEG Ratio0.03
Price to Book (P/B)1.75
Price to Sales (P/S)0.00
P/FCF Ratio-1.29
Enterprise Value/Market Cap0.11
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-4.79
Enterprise Value/Ebitda-0.19
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-1.26
Revenue Forecast (FY)$2.33M
Bulls Say, Bears Say
Bulls Say
Low Leverage / Minimal DebtExtremely low reported debt materially reduces financial risk for a clinical-stage biotech. This structural balance-sheet strength gives management flexibility to prioritize R&D and licensing decisions without near-term pressure from interest or mandatory debt servicing, aiding long-term program development.
Meaningfully Improving Loss TrendA marked reduction in operating losses across periods reflects successful cost control or program prioritization. Sustained improvement in loss levels increases the odds that future financing needs shrink or that partnering becomes more attractive, improving the durability of operations over months.
Focused Therapeutic PipelineA clear strategic focus on hyperuricemia and kidney disease concentrates R&D resources on a defined unmet medical need. This specialization can speed clinical development, attract specialist partners or acquirers, and create longer-term value if lead assets advance through trials or regulatory milestones.
Bears Say
No Revenue / Ongoing Net LossesAbsence of product revenue and recurring net losses mean the company lacks internal cash generation to fund operations. Over a multi-month horizon this structural deficiency forces reliance on external financing and increases execution risk if capital markets or partner interest tighten.
Persistent Negative Operating And Free Cash FlowConsistent negative OCF and FCF across reporting periods show the company cannot self-fund development. Declining free cash flow growth (~-23%) exacerbates runway pressure and raises the likelihood of dilutive financings or constrained trial progress absent new capital or strategic deals.
Thinning Equity Base / Reliance On External FundingA materially reduced equity base weakens the capital cushion available to absorb future losses or disappointing trial outcomes. Structurally, this increases dependence on external funding and raises dilution and negotiation risk when seeking partnerships or financing over the next several months.
XORTX Therapeutics Inc News
XRTX FAQ
What was XORTX Therapeutics Inc’s price range in the past 12 months?
XORTX Therapeutics Inc lowest stock price was $1.73 and its highest was $7.05 in the past 12 months.
What is XORTX Therapeutics Inc’s market cap?
XORTX Therapeutics Inc’s market cap is $3.55M.
When is XORTX Therapeutics Inc’s upcoming earnings report date?
XORTX Therapeutics Inc’s upcoming earnings report date is Aug 13, 2026 which is in 63 days.
How were XORTX Therapeutics Inc’s earnings last quarter?
XORTX Therapeutics Inc released its earnings results on May 16, 2026. The company reported -$0.58 earnings per share for the quarter, missing the consensus estimate of N/A by -$0.58.
Is XORTX Therapeutics Inc overvalued?
According to Wall Street analysts XORTX Therapeutics Inc’s price is currently Overvalued.
Does XORTX Therapeutics Inc pay dividends?
XORTX Therapeutics Inc pays a Quarterly dividend of $0.075 which represents an annual dividend yield of N/A. See more information on XORTX Therapeutics Inc dividends here
What is XORTX Therapeutics Inc’s EPS estimate?
XORTX Therapeutics Inc’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does XORTX Therapeutics Inc have?
XORTX Therapeutics Inc has 1,546,988 shares outstanding.
What happened to XORTX Therapeutics Inc’s price movement after its last earnings report?
XORTX Therapeutics Inc reported an EPS of -$0.58 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -9.686%.
Which hedge fund is a major shareholder of XORTX Therapeutics Inc?
Currently, no hedge funds are holding shares in XRTX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
XORTX Therapeutics Inc
Based in Vancouver, Canada, XORTX Therapeutics Inc. is a biopharmaceutical firm dedicated to discovering and bringing to market treatments for a variety of conditions, including progressive kidney disorders, diabetes, insulin resistance, metabolic syndrome, and infections. The company's pipeline includes XRx-008, a late-stage clinical program addressing autosomal dominant polycystic kidney disease; XRx-101, an agent designed to reduce uric acid levels in COVID-19 patients to prevent acute kidney injury and its associated health issues; and XRx-221, a series of xanthine oxidase inhibitor candidates aimed at treating diabetic nephropathy. Furthermore, XORTX Therapeutics collaborates with the Icahn School of Medicine to research the occurrence of acute kidney injury and elevated uric acid in patients hospitalized with COVID-19.
Technical Analysis
Aptose Biosciences
―
Kane Biotech
―
Quest Pharmatech
―
BioVaxys Technology
―
Doseology Sciences
―
Ownership Overview
9.10%
Insiders
1.08% Other Institutional Investors
89.82% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---